Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Применение ингибиторов ангиотензинпревращающего фермента при ишемической болезни сердца: важно ли правильно выбрать препарат?
Применение ингибиторов ангиотензинпревращающего фермента при ишемической болезни сердца: важно ли правильно выбрать препарат?
Остроумова О.Д., Фомина В.М. Применение ингибиторов ангиотензинпревращающего фермента при ишемической болезни сердца: важно ли правильно выбрать препарат? Consilium Medicum. 2014; 16 (10): 68–72.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр). Кардиоваск. терапия и профилактика. 2008; (Прил. 4), 7 (6).
2. Клиническая фармакология. Под ред. В.Г.Кукеса. Изд. 4-е. М.: ГЭОТАР-Медиа, 2008; с. 392–5.
3. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
4. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145–53.
5. Teo KK, Burton JR, Buller CE et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000; 102: 1748–Б4.
6. Pitt B, O`Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved ventricular function. Am J Cardiol 2001; 87: 1058–63.
7. Hermans WR, Foley DP, Rensing BJ et al. The Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MERCATOR) Study Group. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions–further evidence for the restenosis paradox. Am Heart J 1994; 127: 483–94.
8. PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.
9. Dzau VJ, Berstien K, Celermajer D et al. The relevance of tissue ACE: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (Suppl.): 1L–20L.
10. Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther 2007; 21 (4): 269–79.
11. Ceconi C, Francolini G, Bastianon D et al. Differences in the effect of angiotensinconverting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007; 21 (6): 423–9.
12. Писаржевский С.А. Проницаемость эндотелия и атеросклероз. Кардиология. 2005; 12; с. 27–42.
13. Ceconi C, Fox K, Remme W et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
14. Карпов Ю.А. Периндоприл: клиническая эффективность у всех больных с сосудистым заболеванием или высоким его риском через вазопротекцию. Cons. Med. (Украина). 2010; 11:
с. 32–6.
15. Kränkel N, Katare RG, Siragusa M et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circulation Res 2008; 103: 1335–43.
16. Van Os R, Kamminga LM, de Haan G. Stem cell assay: Something old, something new, something borrowed. Stem Cells 2004; 22: 1181–90.
17. Xu Q. Stem cells and transplant arteriosclerosis. Circ Res 2008; 102: 1011–24.
18. Silvestre JS, Levy BI. Circulating progenitor cells and cardiovascular outcomes: latest evidence on angiotensin-converting enzyme inhibitors. Eur Heart J 2009; 11 (Suppl. E): E17–E21; doi:10.1093/eurheartj/sup020
19. Ceconi C, Francolini G, Olivares A et al. Angiotensinconverting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1–6.
20. Rodriguez-Granillo GA, Vos J, Bruining N et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril’s proSPective Effect on Coronary aTherosclerosis by angiography and IntraVascular ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159–63.
21. Rodriguez-Granillo GA, de Winter S, Bruining N et al. Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. Eur Heart J 2007; 28: 2326–31.
22. Telejko E. Perindopril – arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007; 23: 953–60.
2. Клиническая фармакология. Под ред. В.Г.Кукеса. Изд. 4-е. М.: ГЭОТАР-Медиа, 2008; с. 392–5.
3. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomased, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.
4. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145–53.
5. Teo KK, Burton JR, Buller CE et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The simvastatin/enalapril coronary atherosclerosis trial (SCAT). Circulation 2000; 102: 1748–Б4.
6. Pitt B, O`Neill B, Feldman R et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved ventricular function. Am J Cardiol 2001; 87: 1058–63.
7. Hermans WR, Foley DP, Rensing BJ et al. The Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MERCATOR) Study Group. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions–further evidence for the restenosis paradox. Am Heart J 1994; 127: 483–94.
8. PEACE Trial investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058–68.
9. Dzau VJ, Berstien K, Celermajer D et al. The relevance of tissue ACE: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (Suppl.): 1L–20L.
10. Bots ML, Remme WJ, Luscher TF et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial Cardiovasc Drugs Ther 2007; 21 (4): 269–79.
11. Ceconi C, Francolini G, Bastianon D et al. Differences in the effect of angiotensinconverting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007; 21 (6): 423–9.
12. Писаржевский С.А. Проницаемость эндотелия и атеросклероз. Кардиология. 2005; 12; с. 27–42.
13. Ceconi C, Fox K, Remme W et al. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. Cardiovasc Res 2007; 73: 237–46.
14. Карпов Ю.А. Периндоприл: клиническая эффективность у всех больных с сосудистым заболеванием или высоким его риском через вазопротекцию. Cons. Med. (Украина). 2010; 11:
с. 32–6.
15. Kränkel N, Katare RG, Siragusa M et al. Role of kinin B2 receptor signaling in the recruitment of circulating progenitor cells with neovascularization potential. Circulation Res 2008; 103: 1335–43.
16. Van Os R, Kamminga LM, de Haan G. Stem cell assay: Something old, something new, something borrowed. Stem Cells 2004; 22: 1181–90.
17. Xu Q. Stem cells and transplant arteriosclerosis. Circ Res 2008; 102: 1011–24.
18. Silvestre JS, Levy BI. Circulating progenitor cells and cardiovascular outcomes: latest evidence on angiotensin-converting enzyme inhibitors. Eur Heart J 2009; 11 (Suppl. E): E17–E21; doi:10.1093/eurheartj/sup020
19. Ceconi C, Francolini G, Olivares A et al. Angiotensinconverting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol 2007; 577: 1–6.
20. Rodriguez-Granillo GA, Vos J, Bruining N et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the PERindopril’s proSPective Effect on Coronary aTherosclerosis by angiography and IntraVascular ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159–63.
21. Rodriguez-Granillo GA, de Winter S, Bruining N et al. Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. Eur Heart J 2007; 28: 2326–31.
22. Telejko E. Perindopril – arginine: benefits of a new salt of the ACE inhibitor perindopril. Curr Med Res Opin 2007; 23: 953–60.
Авторы
О.Д.Остроумова, В.М.Фомина
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.